Some people use Zollinger-Ellison syndrome and gastrinoma interchangeably. Learn the similarities and differences between the ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...